Clinical trials: Circulating Tumor DNA (ctDNA)
Lung Cancer
Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer
The investigators aim to identify novel circulating methylated biomarkers for early lung cancer detection as well as to develop new technologies that are clinically applicable with high sensitivity and specificity.
- Trial name
- NCT04814407
- Testing
- Blood-derived DNA methylation detection
- Where
- Taiwan
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Neoplasm Malignant
Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA
This study will evaluate the diagnostic performance of liquid biopsy for identifying molecular abnormalities among patients managed by the Multidisciplinary Molecular Biology Meeting.
- Trial name
- TARGET (NCT06606366)
- Testing
- Blood sample taken for the liquid biopsy
- Where
- France
- Volunteers
- 238 people
- Sponsor
- Centre Antoine Lacassagne
Lung Neoplasms, EGFR Gene Mutations
Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring activating epidermal growth factor receptor (EGFR) mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from…
- Trial name
- LiquidLung-O (NCT02769286)
- Testing
- Osimertinib
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Chonnam National University Hospital